

Quantitative MRI and histopathology detect remyelination in inactive multiple sclerosis lesions

Vanessa Wiggermann^{1,2,3}, Verena Endmayr^{4,5}, Eneidino Hernández-Torres^{3,6}, Romana Höftberger⁴, Gregor Kasprian⁷, Simon Hametner^{4,5,*}, and Alexander Rauscher^{1,2,8,9,*}

¹Department of Physics and Astronomy, University of British Columbia, Canada; ²Department of Pediatrics, University of British Columbia, Canada; ³Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research; Copenhagen University Hospital Amager & Hvidovre, Denmark; ⁴Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria; ⁵Centre for Brain Research, Medical University of Vienna, Austria; ⁶Faculty of Medicine (Division Neurology), University of British Columbia, Canada; ⁷Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Austria; ⁸Department of Radiology, University of British Columbia, Canada; ⁹BC Children's Hospital Research Institute, University of British Columbia, Canada; *equal contribution

This work is submitted for peer-review to Brain Pathology.

Magnetic resonance imaging (MRI) of focal or diffuse myelin damage or remyelination may provide important insights into disease progression and potential treatment efficacy in multiple sclerosis (MS). We performed post-mortem MRI and histopathological myelin measurements in seven progressive MS cases to evaluate the ability of three myelin-sensitive MRI scans to distinguish different stages of MS pathology, particularly chronic demyelinated and remyelinated lesions. At 3 Tesla, we acquired two different myelin water imaging (MWI) scans and magnetization transfer ratio (MTR) data. Histopathology included histochemical stainings for myelin phospholipids (LFB) and iron as well as immunohistochemistry for myelin proteolipid protein (PLP), CD68 (phagocytosing microglia/macrophages) and BCAS1 (remyelinating oligodendrocytes). Mixed-effects modelling determined which histopathological metric best predicted MWF and MTR in normal appearing and diffusely abnormal white matter, slowly expanding, inactive, remyelinated and ischemic lesions. Both MWI measures correlated well with each other and histology across regions, reflecting the different stages of MS pathology. MTR data showed a considerable influence of components other than myelin and a strong dependency on tissue storage duration. Both MRI and histology revealed increased myelin densities in inactive compared with slowly expanding lesions. Chronic inactive lesions harboured single scattered myelin fibres indicative of low-level remyelination. Mixed-effects modelling showed that smaller differences between white matter areas were linked to PLP densities and only to a smaller extent confounded by iron. MWI reflects differences in myelin lipids and proteins across all levels of myelin densities encountered in MS, including low-level remyelination in chronic inactive lesions.

Keywords: remyelination | histopathology | myelin protein | MRI | iron

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), leading to the formation of focal areas of destruction, phagocytosis and digestion of CNS myelin sheaths. Remyelination may follow demyelination (1), but the proportion of remyelinated MS lesions varies greatly between individuals at autopsy (2). Fostering remyelination reduces axonal loss and may thus curtail MS progression (3), rendering it an important target of new therapeutic trials. Non-invasive myelin quantification by means of magnetic resonance imaging (MRI) will be a key component of such trials (4). Among the many MRI techniques for assessing myelin in vivo, multi-echo spin-echo T₂ MWI (5–9) is considered one of the most myelin-specific (10–13) as it separately

quantifies the MRI signal from water protons in the myelin phospholipid bilayers. The mobility of these protons is highly restricted, resulting in a faster T₂ decay than water protons within axons, cell bodies and the extracellular space. The ratio of the short T₂ signal component over the total water signal, termed myelin water fraction (MWF), is considered a surrogate measure of myelin content (5, 14).

Here, we compared three MRI-based myelin scans for the quantitation of myelin in seven progressive MS cases. MS lesions in various stages of de- and remyelination, normal appearing and diffusely abnormal white matter were included and characterized with histopathology and MRI-based myelin measures: 3D multi-echo T₂ gradient- and spin-echo (GraSE) MWI (15), 3D multi-echo spin-echo MWI (16, 17) and 3D MTR (18). Histopathology included Luxol Fast Blue (LFB) staining for phospholipids and diaminobenzidine-enhanced Turnbull blue (TBB) staining for iron. In addition, immunohistochemical stainings for proteolipid protein (PLP), one of the major myelin proteins, CD68 for phagocytosing microglia/macrophages and BCAS1 staining for remyelinating oligodendrocytes were obtained (19).

Materials and Methods

Post-mortem samples. Seven *post-mortem* brains of progressive MS patients (six with secondary-progressive MS, one with primary-progressive MS) were included. Whole brains had been fixed in 4% neutral-buffered formalin for three to four weeks at room temperature. Four cases from the archive at the Neuroimmunology department of the Center for Brain Research, Medical University of Vienna (MUV), Austria, had been fixed in formalin and stored for 9 to 14 years in 1% formalin diluted in phosphate-buffered saline (PBS) at 4° C. Three cases derived from the Division of Neuropathology and Neurochemistry, MUV, Austria, were fixed and stored in formalin for up to 1 year. Basic epidemiological and clinical data are provided in Table 1.

MRI data acquisition. For Cases 6 and 7, whole brains were available for MRI. Of all other cases, smaller tissue slabs were scanned. Their diameters ranged from 21.1 to 110.2 mm and their thickness from 4.2 to 23.8 mm. Scanning was performed on two identical 3T MRI systems (Philips Achieva, Best, The

The authors have no conflicts of interest to declare relevant to this work. RH has received speaker honoraria from Euroimmun, Novartis and Biogen. VW is a board member of NeuroImage: Clinical.

*Corresponding author. E-mail: vanessaw@drcmr.dk

Table 1. Demographic information of the *post-mortem* brain samples, including approximate time since fixation in years. To preserve anonymity, only age ranges are provided. Causes of death were unrelated to MS and included myocardial infarction, cardiovascular death and pancreatic cancer. Storage time refers to storage time in 1% paraformaldehyde / phosphate-buffered saline (SPMS: secondary progressive MS; PPMS: primary progressive MS; M: male; F: female)

	Age w/i [yrs]	Sex	Clinical course	Disease dur. [yrs]	Storage [yrs]
Case 1	31-35	M	SPMS	10.0	10.0
Case 2	41-45	M	SPMS	11.4	14.0
Case 3	46-50	F	SPMS	37.0	9.0
Case 4	66-70	M	PPMS	7.3	12.0
Case 5	61-65	F	SPMS	33	< 1
Case 6	51-55	M	SPMS	24	< 1
Case 7	56-60	F	SPMS	34	< 1

54 Netherlands) in 2015-2016; four cases at the University of
 55 British Columbia (UBC) and three cases at MUV. For all
 56 samples, we acquired 32-echo 3D-GraSE T_2 data for MWI
 57 ($TE/\Delta TE/TR = 10/10/719$ ms, reconstructed $0.9 \times 0.9 \times$
 58 1.5 mm^3) (15). 3D-MTR images were acquired for all cases,
 59 except Case 6 ($TE/TR = 3.7/84.6$ ms, reconstructed $0.9 \times$
 60 $0.9 \times 2 \text{ mm}^3$, flip angle(*exc/mtc*) = $18^\circ/520^\circ$, $\Delta f = 1.1$ kHz
 61 below Larmor frequency). Data acquisition at UBC (Cases
 62 1-4) also included 3D multi-echo spin-echo imaging (CPMG
 63 – Carr-Purcell Meiboom-Gill, $TE/\Delta TE/TR = 10/10/1200$
 64 ms, reconstructed $0.9 \times 0.9 \times 3 \text{ mm}^3$) (16, 17). T_2 -weighted
 65 images were acquired for registration purposes at $TE/TR =$
 66 $100 \text{ ms}/2500 \text{ ms}$, $0.66 \times 0.66 \times 0.7 \text{ mm}^3$. Acquisition parameters
 67 were minimally adapted to adjust for the different sample sizes.
 68 Only for Case 5, the 3D-GraSE sequence was substantially
 69 changed necessitated by the much larger field-of-view. The
 70 study and tissue scanning protocol were approved by the
 71 clinical research ethics boards of both sites (UBC: H15-011,
 72 MUV: EK Nr. 1491-2017).

73 **MRI data processing.** Data processing and analysis was imple-
 74 mented in MATLAB 2017b. MWF was computed as previously
 75 described (5, 20). Briefly, T_2 distributions were obtained us-
 76 ing the extended phase graph algorithm (21) and regularized,
 77 non-negative least squares fitting. T_2 distributions of all tissue
 78 samples in multiple white matter (WM) regions were con-
 79 sulted. Subsequently, the MWF was determined as the T_2
 80 signal fraction between 12 – 25 ms relative to all water (intra-
 81 /extracellular water T_2 range: 25 – 100 ms). MTR maps were
 82 calculated as the ratio of the signal difference between the on-
 83 resonance and off-resonance scan relative to the off-resonance
 84 scan (18).

85 **Tissue Preparation.** After scanning, whole-brain cases were
 86 cut into 1 cm thick coronal double-hemispheric slices. All
 87 other tissue slabs were directly processed for histology. Sam-
 88 ples were dehydrated (Miles Scientific™ autotechnicon device)
 89 and embedded in paraffin. Paraffin blocks were cut into $10 \mu\text{m}$
 90 thick serial sections with a tetrandier microtome (R. Jung AG,
 91 Heidelberg). Sections were stained for hematoxylin and eosin
 92 (H&E) to assess general pathology, Luxol fast blue – periodic-
 93 acid Schiff (LFB-PAS) to visualize myelin and classify MS
 94 lesions, and diaminobenzidine (DAB)-enhanced TBB to detect

iron (22). Iron is stored in myelin-forming oligodendrocytes,
 but also in myelin itself and is a known confounder to MWI and
 MTR (23–25). Immunohistochemistry for mouse monoclonal
 PLP (Serotec, MCA839G, dilution 1:1000) was performed by
 heat-steaming sections in ethylenediaminetetraacetic acid
 (EDTA, pH 9.0, 1h) for antigen retrieval. Unspecific anti-
 body binding was blocked by incubation in 10% fetal calf
 serum (FCS) diluted in Dako wash buffer (DAKO, 20 min,
 room temperature). After overnight-incubation at 4°C , a
 biotinylated donkey anti-mouse secondary antibody was ap-
 plied. Sections were then incubated with avidin-conjugated
 horseradish peroxidase (Sigma Aldrich, dilution 1:500 in 10%
 FCS/DAKO, 1h, room temperature) and developed with the
 chromogen DAB, producing a brown PLP signal. For CD68
 (Dako, M0814, Clone KP1, dilution 1:2000) and BCAS1 (Santa
 Cruz, sc-136342, dilution 1:4000), sections were steamed in
 TRIS buffer (pH 6.0, 1h). Primary antibodies were applied
 overnight at 4°C . After application of an appropriate biotin-
 ylated secondary anti-mouse antibody, the Envision system was
 used according to the manufacturer’s protocol. Stainings were
 visualized by DAB development for 2×5 minutes, producing a
 brown reaction product. Stainings were scanned using an Agfa
 Duoscan® device under standardized brightness conditions, at
 800 pixels/inch, and saved as RGB TIFF.




Fig. 1. Overview of processing pipeline. Differently stained histology sections were aligned with 2D FSL FLIRT. To register all quantitative images, first a pipeline was established based on the 3D T_2 scans, which were reoriented and resliced to match the histology. Registration between histology and MRI was performed using NiftyReg. Quantitative maps were then registered to the 3D T_2 and the already established pipeline and registration matrices were applied.

MRI-histology registration. Figure 1 provides an overview of the MRI-histology registration procedure. Histology images were downsampled by a factor of two along both dimensions. LFB-PAS and PLP sections were colour-deconvolved using ImageJ version 1.43r (A.C. Ruifrok, NIH, Bethesda, MD, USA) to extract the blue channel, i.e. the LFB dye, of the LFB-PAS double-stained sections and the red channel, i.e. the DAB dye, of the hematoxylin-counterstained PLP sections. Because mounting of the sections on glass slides can introduce small 2D distortions, TBB and PLP were registered to the LFB section using 2D FSL FLIRT (26) (default parameters, five degrees of freedom). Initial registrations utilized sections prior to colour

131 deconvolution. Registration matrices were then applied to the
132 lower-contrast, colour-deconvolved sections.

133 Within-MRI and histology-MRI registrations were per-
134 formed using NiftyReg's aladin and f3d (default parameters)
135 (27). T₂-weighted MRIs were reoriented and sliced to match
136 the histology section plane. To approximate the resolutions,
137 reformatted images were up-sampled and histology images
138 further down-sampled. Manual corrections, such as removal of
139 tissue from unrelated sections, were performed for all cases in-
140 dividually. Lastly, registered images were up-sampled to match
141 the histology resolution. MRI data were sent to the histology
142 space to avoid altering the regions-of-interest (ROIs), which
143 were manually defined on the histology sections in FSLview.
144 For the quantitative analysis, all 3D MRIs were registered to
145 the T₂-weighted images. Linear registrations were performed
146 using individual echoes of the quantitative data (default pa-
147 rameters). Subsequently, quantitative maps were transformed
148 using NiftyReg's resample and were then subjected to the same
149 pipeline as the T₂-weighted images, i.e. volume re-orientation,
150 slice selection and mapping to histology.

151 **Manual ROI definition.** ROIs were identified by microscopical
152 inspection of H&E, LFB-PAS and PLP-stained slices using
153 an Olympus BX50[®] microscope by two readers (VE, SH).
154 Non-lesional normal appearing white matter (NAWM) was
155 identified by well-preserved myelin in both LFB-PAS and
156 PLP stainings. Diffusely abnormal white matter (DAWM)
157 had ill-defined areas of LFB-PAS but no PLP reduction (28).
158 Lesional WM included slowly expanding lesions (SEL), in-
159 active lesions (InaL), shadow plaques (SdP) and ischemic
160 lesions (IsL). Slowly expanding lesions had few LFB- and PLP-
161 positive myelin degradation products within phagocytes at
162 the lesion borders, while their centers were almost completely
163 devoid of myelin in the PLP and LFB stainings. Macrophages
164 in the slowly expanding lesion cores were LFB-negative and
165 frequently harbored PAS-positive material. Inactive lesions
166 occasionally showed PAS-positive macrophages, but no LFB-
167 or PLP-positive myelin remnants within phagocytes anywhere.
168 Shadow plaques displayed sharp borders of LFB-myelin reduc-
169 tion, resulting from thinner remyelinating sheaths, and evenly
170 distributed intact myelin throughout the plaque. We further
171 encountered circumscribed lesions of myelin reduction but not
172 depletion, similar to shadow plaques. However, these lesions
173 had ill-defined borders and increased LFB-intensity around
174 blood vessels traversing the lesions, i.e. a non-homogenous
175 LFB-intensity reduction within the lesion. Their coarse tex-
176 ture indicated pronounced widening of the extracellular spaces.
177 These were labeled ischemic lesions. ROIs were manually out-
178 lined on the LFB-PAS images. Anatomical and pathological
179 boundaries were generously spared. To account for small differ-
180 ences in slice matching and imperfect registration, the masks
181 were adapted to optimally match the TBB and PLP scans and
182 the registered T₂-weighted MRI. CD68 stainings were qualita-
183 tively evaluated for the distinction between slowly expanding
184 (CD68 rim of microglia/macrophages present) and inactive (no
185 CD68 rim present) lesions. BCAS1 stainings were evaluated
186 with a counting grid in NAWM, DAWM and centers of slowly
187 expanding, inactive and remyelinated lesions. The evaluated
188 area covered 1 mm², i.e. four neighboring visual fields at 20x
189 magnification. Only clearly and strongly BCAS1-positive glial
190 cells were counted.

Data and statistical analysis. ROIs were automatically
matched using their voxel location and the classification
assigned to each ROI. We applied bwconncomp, a region-
detection algorithm in MATLAB, to correlate histological and
MRI values in all ROIs. Gray-scale medians for each ROI were
calculated in all MRI and histological images, representative
of each ROI's myelin state.

Differences between slowly expanding and inactive lesions
were assessed by a two-sided rank sum test (5% significance
level). Correlations were performed on a per-case basis to
suppress the influence of varying post-mortem delays, forma-
lin fixation and storage times. Weighted average within-case
slopes, intercepts and p-values were obtained, with weights
represented by the variance of the individual within-section
slopes, intercepts and correlation coefficients, respectively. Av-
erage correlation coefficients were determined by transforming
the r-values using Fisher's z-transformation and subsequently
computing the hyperbolic tangent of the average of the trans-
formed r-values. Finally, a linear mixed effects regression
model was used in R to determine the standardized correlation
coefficients as a measure of relative importance of LFB, PLP,
TBB and storage time in predicting MWF and MTR (lm.beta
package) (29). The data offset was modelled with two random
factors that accounted for inter- and intra-subject variability.
Collinearity between predictors was evaluated using the vif
function (30). BCAS1 count differences were tested using
an ANCOVA. ROI was used as fixed factor and slice ID as
random factor to correct for multiple data points derived from
the same cases.

Results

Matching MRI and histology data, we obtained 27 section
planes from the seven MS cases. GraSE MWF data of Case 5
were excluded due to unexpectedly low contrast, presumably
related to changes in acquisition. One section from Case 6
was also excluded due to unreliable GraSE MWF signal. All
cases showed pathological alterations typical of progressive MS,
including DAWM, slowly expanding and inactive lesions as
well as remyelinated shadow plaques. Classical active lesions
were not observed. Major confounding pathology was noted
in Case 7, which harboured ischemic lesions together with
severely atherosclerotic large meningeal arteries. Only lesions
of either clear ischemic or MS origin were analyzed. In total,
610 ROIs were outlined (median size 5.69 mm², range: 0.14
mm²– 32.09 mm²). Figure 2 exemplifies matched MRI and
histology with corresponding ROIs from four MS cases.

Histological stainings of one section of Case 7 are exem-
plified in Figure 3. NAWM was predominantly found in sub-
cortical WM areas, since the progressive MS cases displayed
typical widespread diffuse myelin injury in deep WM areas
(Fig. 3g, black arrows). Inactive, but not slowly expanding le-
sions, harboured scattered thin myelin sheaths in their centers
(compare Fig. 3i & Fig. 3j). BCAS1 staining (Fig. 3h) showed
the highest cell densities in peri-plaque WM close to the rim of
slowly expanding lesions (Fig. 3k), but on average hardly any
positive cells in the lesion cores. A subset of inactive lesions,
however, displayed clustered positive cells in the lesion center
(Fig. 3l). Upon morphological evaluation of BCAS1+ cells, we
noted that one portion of positive cells




Fig. 3. Histological sections of a double-hemispheric coronal slice level of Case 7. (A) CD68 immunohistochemistry revealed accumulated activated microglia and macrophages at the edge of a slowly expanding periventricular lesion (left black square, enlarged in C), but not at the inactive periventricular lesion edge (right black square, enlarged in D). (B) Similarly, TBB staining showed iron accumulation at the slowly expanding (E), but not at the inactive lesions edge (F). Both lesions had iron loss in their centers. In WM, iron staining was highest subcortically, gradually decreased in DAWM and towards lesions, and was lowest within lesion centers. (G) LFB-PAS myelin staining visually distinguished areas of NAWM (mainly subcortically and in the capsula interna), DAWM and MS lesions. Black arrows indicate the ill-defined DAWM, characterized by reduced myelin intensity. Both periventricular MS lesions (enlarged in I and J) showed myelin loss. Notably, scattered thin myelin sheaths were present within some inactive lesion centers (J, high magnification inset with arrows), but never in slowly expanding lesions (I). Occasional macrophages with PAS-positive cytoplasmic inclusions, indicative of remote demyelination, were found. (H) BCAS1 immunohistochemistry revealed moderate immunoreactivity in myelin, rendering exquisite histological myelin contrast. Strongly BCAS1-positive glial cells without processes and dystrophic morphology accumulated in areas of WM damage, such as DAWM (see quantitative data) and WM abutting slowly expanding lesion edges (K). Process-bearing actively remyelinating oligodendrocytes could be found exclusively in few inactive lesions (L) and shadow plaques.




Fig. 2. Qualitative comparison of the histology and co-registered MRI data for four sections from four cases (A: Case 4, B: Case 7, C: Case 1, D: Case 2). The histological images were contrast-inverted to visually match the MRI contrasts so that lower intensities represent lower myelin or iron concentrations. Co-registration achieved good matching of the MRI to the LFB stains, which were chosen as histology reference. ROIs were centered in representative regions, yielding good local correspondence of ROIs on visual inspection. The ROIs were drawn with a gap to avoid partial volume effects at anatomical or lesion borders. (Acronyms: normal appearing WM (NAWM); diffusely abnormal WM (DAWM); inactive lesions (InaL); shadow plaques (SdP); slowly expanding lesions (SEL); ischemic lesions (IsL))




Fig. 4. Correlation of all MRI metrics. Both MWF estimates showed excellent agreement with a minimal intercept (A), whereas correlations between MWF and MTR depended on storage times (B,C). Correlations between MWF and MTR were significant in tissues with storage times of < 1 year (dotted line) and were non-significant for tissues with extended storage time > 9 years (dashed line). Note that CPMG data were only available for samples with extended storage time (C). Symbols indicate different cases; colors distinguish different tissue types. (Acronyms: normal appearing WM (NAWM); diffusely abnormal WM (DAWM); inactive lesions (InaL); shadow plaques (SdP); slowly expanding lesions (SEL); ischemic lesions (IsL))

gression intercepts in all correlations with MTR were different from zero. In cases stored < 1 year, the intercept for GraSE MWF and MTR was 19.3 a.u.. In cases with extended storage, the intercepts were 14.2 a.u. and 14.5 a.u., when comparing GraSE MWF and CPMG MWF with MTR, respectively.

Histological and MRI-based myelin measurements in different ROIs

Figure 5 displays the stratification of histological optical densities and MRI data according to ROI. WM LFB (Fig. 5a) and PLP (Fig. 5c) optical densities were highest in NAWM, followed by DAWM, shadow plaques and inactive lesions, and were lowest in slowly expanding lesions. LFB and PLP densities in ischemic lesions resembled those of shadow plaques. In contrast to LFB, PLP hardly differed between NAWM and DAWM. Iron was lower in DAWM compared to NAWM, and markedly depleted in slowly expanding and inactive lesions. In shadow plaques, iron densities ranged between the densities of DAWM and demyelinated lesions. Few high NAWM iron densities were derived from Case 1.

Of all MRI metrics (Figs. 5b and 5d, CPMG data not shown), relative differences in GraSE MWF between ROIs most closely matched the LFB and PLP intensity distributions (Figs. 5a and 5c). All myelin MRI metrics were reduced in DAWM compared to NAWM, though less so than LFB. MWF was lower in all WM lesions than in NAWM or DAWM. In shadow plaques and ischemic lesions, MWF was between slowly expanding lesions and DAWM, best reflecting LFB and PLP relations. By contrast, MTR in shadow plaques exceeded NAWM MTR. All three MRI measures yielded higher values in inactive compared to slowly expanding lesions, sensitively reflecting histological myelin data. LFB ($p < 0.001$), GraSE MWF ($p = 0.016$) and MTR ($p < 0.001$) were all significantly higher in inactive compared to slowly expanding lesions, also after Bonferroni correction. BCAS1 counts, indicative of the number of actively remyelinating oligodendrocytes, were generally in line with the observations from LFB and MWF. The number of BCAS1+ cells in lesion areas was generally lower than counts in NAWM and DAWM. Slowly expanding lesions were found to have, on average, slightly lower BCAS1+ counts than inactive lesions and shadow plaques, although the differ-

had strong cytoplasmic immunoreactivity, and either absent or very short and dystrophic-appearing processes. This type of BCAS1+ cell morphology was found in NAWM, DAWM and was most prominent in periplaque WM close to slowly expanding lesion (Fig. 3k). Conversely, BCAS1+ cells in inactive and remyelinated lesion cores had multiple, partly parallel processes (Fig. 3l). Ischemic lesions were reminiscent of shadow plaques regarding their myelin densities but differed morphologically. Shadow plaques were characterized by a sharp border and homogeneously thin myelin sheaths in the plaque area. By contrast, ischemic lesions showed a gradient of myelin intensity, including ill-defined borders, as well as a coarse lesion tissue texture with loss of whole myelin fibers, but preservation of normal myelin sheath thickness in the remaining fibers.

Comparison of MRI-based myelin estimates. Fig. 4a displays the regression between GraSE and CPMG MWF ($R^2 = 0.862$, slope = 0.858 %/%, intercept = -0.42% MWF), which demonstrates excellent agreement of these two myelin water scans. However, the regression of CPMG MWF and MTR was insignificant (Fig. 4c, $R^2 < 0.01$). Note that CPMG data were only acquired in samples with storage times longer than 9 years. The MTR – GraSE MWF relationship was modelled by two different, storage time dependent regression lines (Fig. 4b). GraSE MWF and MTR correlated significantly in tissue blocks with storage times of < 1 year, ($R^2 = 0.436$), but not in those with extended storage times ($R^2 < 0.01$). Notably, the re-




Fig. 5. Comparison of quantitative MRI values and optical densities across regions of interest. Panels on the left display the histological density measurements (LFB (A), PLP (C), TBB (E)), panels on the right the MRI myelin measurements (GraSE MWF (B), MTR (D)). Panel F displays the separately obtained BCAS1 counts. LFB and PLP differences between ROIs, including in lesions, were well reflected in both MWF measurements. By contrast, MTR changes appeared more closely linked to the TBB staining intensities, and MTR values overlapped between regions. Note that the data collection for CPMG and MTR were incomplete, thus not all ROIs are present in the MTR plot. (Acronyms: normal appearing WM (NAWM); diffusely abnormal WM (DAWM); inactive lesions (InaL); shadow plaques (SdP); slowly expanding lesions (SEL); ischemic lesions (IsL))

related to DAWM GraSE MWF and MTR. Similar to NAWM, MRI myelin values in shadow plaques were predicted by PLP, storage time and in part LFB. In line with the above-described differences between inactive and slowly expanding lesions, the mixed effects model revealed some association between LFB and MWF in inactive, but not in slowly expanding lesions. The latter only showed a dependency for MTR on LFB. Standardized regression coefficients, i.e. the amount of change that a variation in each of the predictor variable yields in the MRI-measured myelin values, are provided together with the p-values in [Table 2](#).

Discussion

We assessed the ability of three myelin-sensitive MRI techniques to differentiate various degrees of myelin damage, recovery and lesional activity in a larger sample of progressive MS cases. Using histochemical and immunohistochemical stainings for myelin, we showed low levels of myelin in completely inactive lesions. We suggest that this myelin signal may represent remyelination occurring in chronic MS lesions without microglia or iron rims. These low myelin levels were conspicuous in the high-magnification of the histological stainings and captured by all investigated myelin-sensitive MRI techniques and in part corroborated by BCAS1 stainings. Importantly, our data showed that BCAS1-positivity is not exclusively a marker for remyelinating oligodendrocytes, but that it also marks degenerating glial cells in DAWM and in the vicinity of the chronic active lesion edges. Detecting and following subtle remyelination in vivo in chronic lesions provides an additional avenue for assessing repair in MS and may be a relevant consideration for trials of remyelinating therapies, which typically are believed to be most efficacious in younger MS lesions.

Comparison of MWF, MTR and histopathological metrics. The excellent agreement of CPMG and GraSE MWF ($R^2 = 0.862$) corroborates in vivo comparisons (15). We attributed the two different relationships of MWF with MTR to storage time. MTR is known to decrease with formaldehyde fixation (31), but longer-term pH changes may also affect MTR similar to other off-resonance techniques (32). NAWM and DAWM showed the most pronounced storage-related MTR shifts of up to 20 a.u., much more than the difference in intercept. Between cases, acquisition differences and differences in iron content affect MTR. Increased TR is known to result in MTR reductions (33), while strong WM iron depletion significantly increases MTR (22, 24, 25). More work is warranted to understand the dependency of MTR on the storage duration after formalin fixation.

Independently, non-zero regression intercepts between MTR and LFB, PLP and the other two MRI myelin measures indicate that MTR reflects not only myelin lipids and proteins but also other tissue characteristics, despite being positively correlated with high R^2 . Although MTR is widely used to detect de- and remyelination (34), other non-aqueous tissue components, such as axonal and glial cell membranes, soluble proteins in the extracellular space, and astrocytic and axonal densities also play a role (35). Inflammation and edema further confound the specificity of MTR for myelin (35, 36), while MWF remains relatively unchanged (37, 38). Note the large overlap in MTR across different tissue types and the relatively high MTR in slowly expanding and inactive lesions, resulting

ence was statistically not significant ($p = 0.987$). Significantly more BCAS1-positive cells were found in damaged DAWM compared to NAWM ($p < 0.001$).

Per-case correlations and average correlation coefficients (data not shown) between the MRI metrics and stainings reflect the findings of [Figs. 4 and 5](#), i.e. strong correlations between myelin MRI metrics and myelin stainings, albeit with a non-zero intercept in correlations with MTR. Exemplarily, [Figure 6](#) presents the GraSE MWF vs. LFB correlations. Note that sections containing only NAWM or DAWM, i.e. no lesions, exhibited typically insignificant, flat correlations and that MWF and MTR values varied between cases.

Despite moderate to strong correlation coefficients across different tissue classes, within tissue class correlation coefficients were substantially smaller. To determine the extent to which LFB, PLP and TBB, in combination, predict the MRI metrics within specific tissue classes, we applied a linear mixed effects model. Data from all cases were included, and time since fixation was added as a fixed effect to account for differences in the MRI metrics related to storage time. [Table 2](#) summarizes the significant contributors that were determined in the regression model. BCAS1 data were not included in the mixed effects model as they were separately obtained and analyzed.

PLP significantly explained variations in NAWM and DAWM GraSE MWF, while CPMG MWF and MTR were strongly influenced by tissue storage time. TBB significantly




Fig. 6. Within-case correlations between LFB and GraSE MWF across all ROIs. In order to suppress between-section deviations, all correlations shown are weighted averages of the individual within-section correlations. Different symbols distinguish data from different sections of a case. Different colors indicate different ROI types. The slopes of the average correlations ranged from 0.06 to 0.15 % MWF per optical density unit. All correlations, except for Case 6, were significant. Case 5 is not shown as the GraSE data were deemed unreliable for analysis. (Acronyms: normal appearing WM (NAWM); diffusely abnormal WM (DAWM); inactive lesions (InaL); shadow plaques (SdP); slowly expanding lesions (SEL); ischemic lesions (IsL))

401 from the non-zero intercept.

402 Limitations of earlier MWI approaches (5, 16), i.e. small
403 field-of-view and very long acquisition times, have been over-
404 come by introducing the 3D GraSE sequence in MWI (15).
405 However, the now widely used GraSE-MWI approach has never
406 been histopathologically validated. Previous MWF histopatho-
407 logical comparison focused on LFB intensities (8) and recently,

408 electron microscopy validated CPMG-MWI in rat spinal cord
409 samples (9). We assessed myelin more broadly, including lipids
410 as well as myelin proteins and iron to explain variations in
411 MWF (28), with CD68 and BCAS1 for further validation.
412 Gradient echoes in the GraSE sequence may make MWF more
413 susceptible to static field inhomogeneities. However, in agree-
414 ment with other work (24), we did not observe differences

Table 2. Linear mixed effects model ANOVA predictors of MR myelin measurements. Unadjusted p-values are reported together with their relative importance coefficients. Values reported in bold font are $p < 0.05$, non-bolded values reflect p-values between 0.05 and 0.1. If no significant factor was reported by the ANOVA (ns) or the largest β -coefficient did not correspond to the significant entry, the highest importance factor is listed in gray in the second half of the respective cell. (Acronyms: normal appearing WM (NAWM); diffusely abnormal WM (DAWM); inactive lesions (InaL); shadow plaques (SdP); slowly expanding lesions (SEL); ischemic lesions (IsL))

Tissue Type	GraSE MWF	CPMG MWF	MTR
NAWM	PLP $p = 0.002$ ($\beta = 0.543$) TBB $p = 0.052$ ($\beta = -0.198$)	Time $p = 0.010$ ($\beta = 0.732$)	Time $p = 0.020$ ($\beta = -0.506$)
DAWM	PLP $p < 0.001$ ($\beta = 0.534$) TBB $p = 0.020$ ($\beta = -0.227$)	Time $p < 0.001$ ($\beta = 0.857$)	PLP $p < 0.001$ ($\beta = 0.233$) LFB $p = 0.003$ ($\beta = 0.174$) TBB $p = 0.016$ ($\beta = -0.132$) Time $p = ns$ ($\beta = -0.346$)
SdP	PLP $p = 0.062$ ($\beta = 0.582$) Time $p = 0.070$ ($\beta = -0.409$)	Time $p = ns$ ($\beta = 0.148$) TBB $p = ns$ ($\beta = -1.076$)	LFB $p = 0.059$ ($\beta = 0.192$)
SEL	PLP $p = ns$ ($\beta = 0.511$)	PLP $p = 0.091$ ($\beta = 0.408$) LFB $p = ns$ ($\beta = -2.650$) Time $p = ns$ ($\beta = 2.656$)	LFB $p < 0.001$ ($\beta = 0.489$)
InaL	LFB $p = 0.084$ ($\beta = 0.255$)	LFB $p = 0.063$ ($\beta = 0.544$) Time $p = ns$ ($\beta = 0.890$)	Time $p = 0.002$ ($\beta = -0.626$) Time $p = 0.002$ ($\beta = -0.626$)
IsL	TBB $p = ns$ ($\beta = 0.423$)		PLP $p = ns$ ($\beta = 0.587$)

415 between GraSE and CPMG MWF, although TBB contributed
416 to the prediction of GraSE MWF in some regions (Table 2).
417 Note that iron was highly variable between cases in the present
418 study, possibly due to reduced tissue iron concentrations in
419 progressive cases with long disease duration (22).

420 Relative differences in MWF between tissues agreed well
421 with the differences in LFB and PLP stainings, including in
422 lesions. This demonstrates excellent sensitivity of MRI-based
423 myelin imaging to the detection of different stages or degrees of
424 de- or remyelination, despite low lesional myelin concentrations.
425 Integrating the different stainings in a multi-linear regression
426 showed that both myelin lipid and protein concentrations are
427 needed to predict variations within tissue classes, such as
428 within DAWM or between different shadow plaques. Notably,
429 LFB and PLP explained much greater variation in MWF than
430 TBB.

431 **Slowly Expanding and Inactive Lesions.** Differently from
432 slowly expanding lesions (39), inactive lesions do not have
433 a rim of degradation products, but both are typically de-
434 scribed as relatively free of myelin containing macrophages,
435 microglial activation, and inflammation in their lesion centers
436 (40). By contrast, we observed non-zero MWF and MTR in
437 inactive lesions and found few, thin myelin sheaths in LFB
438 sections, not seen in slowly expanding lesions (Figure 3). LFB
439 and both MWF and MTR showed consistently higher levels
440 in inactive compared to slowly expanding lesions. Correspond-
441 ingly, the statistical model detected, albeit insignificantly, that
442 LFB influenced GraSE and CPMG MWF for inactive, but not
443 for slowly expanding lesions.

444 Our findings are in line with post-mortem work showing in-
445 significantly higher MTR and macromolecular proton fractions
446 in inactive compared to slowly expanding lesions (35). More-
447 over, in vivo susceptibility and myelin imaging demonstrated
448 that rim lesions have lower myelin values than inactive lesions
449 (41). Most of these studies attributed the lower signal to the
450 greater destructiveness of slowly enhancing lesions. Meanwhile,
451 it has been shown that both slowly expanding and inactive
452 lesions may contain BCAS1+ premyelinating oligodendrocytes,
453 indicating the ability of both lesion types to remyelinate (19).
454 It is believed that while the rim of activated microglia and
455 macrophages exists, it may prevent lesional myelin recovery
456 (39, 42). Our data suggest that inactive lesions, for which the
457 rim has resolved, start to recover some thin myelin sheaths to
458 a degree that the lipid signal can be detected on histological
459 stainings and with myelin-sensitive MRI techniques.

460 Thus, it may be possible to capture varying degrees of
461 late remyelination also in vivo using MRI. All these observa-
462 tions warrant further investigation to better characterize the
463 difference between slowly expanding and inactive lesions.

464 Notably, our data showed that BCAS1+ also stains de-
465 generating glial cells. This is supported by the BCAS1+ cell
466 morphology in areas of DAWM and periplaque WM, where
467 cells had either no or short and twisted dystrophic processes.
468 By contrast, in few areas within inactive or partly remyeli-
469 nated lesions many BCAS1+ cells had extensive branches and
470 formed processes to multiple internodes, yielding a morphology
471 reminiscent of that described for PLP-positive myelinating
472 oligodendrocytes (43). However, this was only found in few
473 lesions and might relate to the transient nature of remyeli-
474 nation.

Normal appearing and diffusely abnormal WM & Shadow
Plaques and Ischemic Lesions. The lower LFB but similar
PLP signal between DAWM and NAWM (Figure 5) agrees
with the lipid abnormality characteristic of DAWM (28). Inter-
estingly, our mixed effects model suggested that more subtle
differences within NAWM and DAWM GraSE MWF relate
to differing PLP-concentrations. TBB also played a role in
distinguishing subtle differences between NAWM and DAWM
regions, in line with the importance of iron for myelin pro-
duction in oligodendrocytes and previously described iron loss
in DAWM (44). Given the widespread diffuse injury, NAWM
ROIs were confined to subcortical regions. These tissue block
areas are more likely to be affected by misregistration errors,
possibly explaining why the MRI-measured NAWM-DAWM
difference was smaller than expected from their LFB intensi-
ties. CPMG and MTR were predominantly related to storage
time or a combination of predicting factors.

Shadow plaques and ischemic lesions were well reflected in
GraSE MWF, but both lesion types had higher MTR than
NAWM and DAWM. This may again relate to the inverse
relationship between MTR and iron concentrations (23, 25).
Note that our shadow plaques yielded non-zero TBB staining,
although they have been generally found to remyelinate with-
out iron recovery (22). Regardless, myelin-related regression
coefficients for GraSE MWF in shadow plaques were noticeably
larger than the TBB coefficients, indicating that iron plays a
minor role in the estimation of MWF in shadow plaques. No
specific histopathological factor predicted MWF or MTR of
ischemic lesions.

Study strengths and limitations. We tested how myelin lipids,
proteins and iron contribute to MWF and MTR. Our data
provide the first validation of the use of the GraSE sequence
for MWI. We demonstrated the sensitivity of these myelin
imaging techniques on a case-by-case basis. Across cases,
we utilized mixed effects modeling to provide a combined
assessment of the role of lipids, proteins, and iron to the MRI
measures, rather than assessing them in isolation. We did not
consider axonal density, which is relevant for MTR (35), due
to its strong collinearity with myelin. Assessing gliosis and
inflammation, however, may help to shed further light on the
observed lesional differences. BCAS1 staining was performed
separately to support our initial findings. Dedicated sample
selection to investigate specific tissue classes or class differences
would be advantageous but was beyond the scope of the work
presented here.

Our investigation included MTR (6), rather than quantita-
tive magnetization transfer (35), as MTR is more frequently
used, both in clinical trials and research. Assessing other
techniques, e.g. T_2^* -based myelin mapping (7, 45), may be of
interest in the future. Although other MRI techniques may
have advantages over traditional MWI acquisitions, including
potentially faster acquisition times (6), higher spatial reso-
lution (46), improved signal-to-noise ratio and lower specific
absorption rates, they are also known to be influenced by
axonal water (12), magnetization transfer effects (11, 36, 47)
or to suffer phase errors due to field inhomogeneities and phys-
iological noise (48, 49). Current MWI approaches (14, 21) also
have the advantage of being model-free, and new developments
in MWI may alleviate limitations in scan time and spatial
resolution (50).

535 Conclusions

536 Both MWI strategies, the original CPMG and the faster
537 GraSE acquisition, as well as MTR reflected the histologically
538 assessed myelin concentrations across tissues and allowed to
539 detect subtle within-tissue class differences. Notably, the
540 range of MWF and MTR values observed in inactive lesions
541 appeared to reflect variable degrees of late, slowly progressing
542 remyelination.

543
544 **Data Availability Statement:** Data are available from the
545 corresponding author upon reasonable request.

546 **ACKNOWLEDGMENTS.** The authors wish to thank Marianne
547 Leisser for supporting the histological analysis at the Medical Uni-
548 versity of Vienna, and Professor Hans Lassmann for allowing them
549 to use tissue from the multiple sclerosis brain bank for this work.
550 We wish to acknowledge the continued research support by Philips
551 Healthcare. This study was supported by the Research Method-
552 ology Grant from the BC Children's Hospital Research Institute
553 (former CFRI) and funding from the National Multiple Sclerosis
554 Society (RG-1507-05301). VW was supported by a graduate student
555 award from the Multiple Sclerosis Society of Canada (EGID
556 2002). VE was supported by funding from the National Multiple
557 Sclerosis Society (RG-1507-05301). EHT was supported by Consejo
558 Nacional de Ciencia y Tecnología (237961). We are grateful for
559 additional support from NSERC (402039-2011, 2016-05371), CIHR
560 (RN382474-418628) and the Milan and Maureen Ilich Foundation.
561 AR is supported by Canada Research Chairs (950-230363).

562 References

563 1. Goldschmidt T., Antel J., König F.B., Brück W., and Kuhlmann T. Remyelination capacity of
564 the MS brain decreases with disease chronicity. *Neurology*, 72(22): 1914–1921, 2009.
565 2. Patrikios P., Stadelmann C., Kutzelnigg C., Rauschka H., Schmidbauer M., Laursen H.,
566 Sorensen P.S., Brück W., Lucchinetti C., and Lassmann H. Remyelination is extensive in
567 a subset of multiple sclerosis patients. *Brain*, 129(12): 3165–3172, 2006.
568 3. Stankoff B., Jadasz J.J., Hartung H.P., Kuery P., Zalc B., and Lubetzki C. Repair strategies
569 for multiple sclerosis: challenges, achievements and perspectives. *Curr Opin Neurol*, 29(3):
570 286–292, 2016.
571 4. Oh J., Ontaneda D., Azevedo C., Klawiter E.C., Absinta M., Arnold D.L., Bakshi R., Calabresi
572 P.A., Crainiceanu C., Dewey B., and Freeman L. Imaging outcome measures of neuroprotection
573 and repair in MS: A consensus statement from NAIMS. *Neurology*, 92: 519–533, 2019.
574 5. MacKay A., Whittall K., Adler J., Li D., Paty D., and Graeb D. In vivo visualization of myelin
575 water in brain by magnetic resonance. *Magn Res Med*, 31:673–677, 1994.
576 6. Nguyen T.D., Wisniewski C., Cooper M.A., Kumar D., Raj A., Spincemaille P., Wang Y., Vartanian
577 T., and Gauthier S.A. T2prep three-dimensional spiral imaging with efficient whole brain
578 coverage for myelin water quantification at 1.5 tesla. *Magn Reson Med*, 67(3): 614–621,
579 2012.
580 7. Alonso-Ortiz E., Levesque I.R., and Pike G.B. MRI-based myelin water imaging: A technical
581 review. *Magn Reson Med*, 73(1): 70–81, 2015.
582 8. Laule C., Leung E., Li D.K.B., and et al. Myelin water imaging in multiple sclerosis: quantita-
583 tive correlations with histopathology. *Mult Scler*, 12(6):747–753, 2006.
584 9. Chen H.S.-M., Holmes N., Liu J., Tetzlaff W., and Kozlowski P. Validating myelin water imaging
585 with transmission electron microscopy in a rat spinal cord injury model. *NeuroImage*, 153:
586 122–130, 2017.
587 10. Schmierer K., Scaravilli F., Altmann D.R., Barker G.J., and Miller D.H. Magnetization transfer
588 ratio and myelin in postmortem multiple sclerosis brain. *Ann Neurol*, 56: 407–415, 2004.
589 11. Zhang J., Kolind S.H., Laule C., and MacKay A.L. How does magnetization transfer influence
590 mcDESPOt results? *Magn Reson Med*, 74(5): 1327–1335, 2015.
591 12. Chang E.H., Argyelan M., Aggarwal M., and et al. The role of myelination in measures of
592 white matter integrity: Combination of diffusion tensor imaging and two-photon microscopy of
593 CLARITY intact brains. *NeuroImage*, 147:253–261, 2017.
594 13. Pareto D., Garcia-Vidal A., Alberich M., and et al. Ratio of t1-weighted to t2-weighted signal
595 intensity as a measure of tissue integrity: Comparison with magnetization transfer ratio in
596 patients with multiple sclerosis. *Am J Neuroradiol*, 41(3):461–463, 2020.
597 14. Whittall K.P., MacKay A.L., Graeb D.A., Nugent R.A., Li D.K., and Paty D.W. In vivo mea-
598 surements of T2 distributions and water contents in normal human brain. *Magn Reson Med*,
599 37(1): 34–43, 1997.
600 15. Prasloski T., Rauscher A., MacKay A.L., Hodgson M., Vavasour I.M., Laule C., and Mädler
601 B. Rapid whole cerebrum myelin water imaging using a 3D GRASE sequence. *NeuroImage*,
602 63:533–539, 2012.
603 16. Kolind S.H., Mädler B., Fischer S., Li D.K.B., and MacKay A.L. Myelin water imaging: im-
604 plementation and development at 3.0T and comparison to 1.5T measurements. *Magn Reson
605 Med*, 62(1):106–115, 2009.
606 17. Mädler B. and MacKay A.L. In-vivo 3D multi-component T2-relaxation measurements for
607 quantitative myelin imaging at 3T. In *Proc Intl Soc Mag Reson Med 14*, page 2112, 2006.

608 18. Finelli D.A., Hurst G.C., Amantia P. Jr., and et al. Cerebral white matter: Technical develop-
609 ment and clinical applications of effective magnetization transfer (mt) power concepts for
610 high-power, thin-section, quantitative mt examinations. *Radiology*, 199:219–226, 1996.
611 19. Fard M.K., van der Meer F., Sánchez P., Cantuti-Castelvetri L., Mandat S., Jäkel S., For-
612 nasiero E.F., Schmitt S., Ehrlich M., Starost L., and Kuhlmann T. BCAS1 expression defines
613 a population of early myelinating oligodendrocytes in multiple sclerosis lesions. *Sci Transl
614 Med*, 9(419): eaam7816, 2017.
615 20. Wiggemann V., Vavasour I.M., Kolind S.H., MacKay A.L., Helms G., and Rauscher A. Non-
616 negative least squares computation for in vivo myelin mapping using simulated multi-echo
617 spin-echo T2 decay data. *NMR Biomed*, page e4277, 2020.
618 21. Prasloski T., Mädler B., Xiang Q.-S., MacKay A., and Jones C. Applications of stimulated
619 echo correction to multicomponent T2 analysis. *Magn Reson Med*, 67(6):1803–1814, 2012.
620 22. Hametner S., Wimmer I., Haider L., Pfeifenbring S., Brück W., and Lassmann H. Iron and
621 neurodegeneration in the multiple sclerosis brain. *Ann Neurol*, 74(6): 848–861, 2013.
622 23. Langkammer C., Krebs N., Goessler W., Scheurer R., Yen K., Fazekas F., and Ropele S.
623 Susceptibility induced gray–white matter MRI contrast in the human brain. *NeuroImage*, 59(2):
624 1413–1419, 2012.
625 24. Birkel C., Birkel-Toegelhofer A.M., Endmayr V., and et al. The influence of brain iron on myelin
626 water imaging. *NeuroImage*, 199:545–552, 2019.
627 25. Birkel C., Birkel-Toegelhofer A.M., Kames C., and et al. The influence of iron oxidative state on
628 quantitative MRI parameters in post mortem human brain. *NeuroImage*, 220:117080, 2020.
629 26. Jenkinson M., Bannister P., Brady M., and Smith S. Improved optimisation for the robust
630 and accurate linear registration and motion correction of brain images. *NeuroImage*, 17(2):
631 825–841, 2002.
632 27. Modat M., Cash D.M., Daga P., Winston G.P., Duncan J.S., and Ourselin S. Global image
633 registration using a symmetric block-matching approach. *J Med Imaging*, 1(2):024003, 2014.
634 28. Laule C., Pavlova V., Leung E., Zhao G., MacKay A.L., Kozlowski P., Traboulsee A.L., Li D.K.,
635 and Moore G.W. Diffusely abnormal white matter in multiple sclerosis: further histologic stud-
636 ies provide evidence for a primary lipid abnormality with neurodegeneration. *J Neuropathol
637 Exp Neurol*, 72(1): 42–52, 2013.
638 29. Vittinghoff E., Glidden D.V., Shiboski S.C., and McCulloch C.E. *Regression methods in bio-
639 statistics: linear, logistic, survival, and repeated measures models*. Springer Science & Busi-
640 ness Media, 2011.
641 30. Lin D., Foster D.P., and Ungar L.H. VIF-Regression: A fast regression algorithm for large data.
642 *J Am Stat Assoc*, 106(493): 232–247, 2011.
643 31. Schmierer K., Wheeler-Kingshott C.A.M., Tozer D.J., Boulby P.A., Parkes H.G. abd
644 Yousry T.A., Scaravilli F. and Barker G.J., Tofts P.S., and Miller D.H. Quantitative magnetic
645 resonance of post-mortem multiple sclerosis brain before and after fixation. *Magn Reson
646 Med*, 59(2): 268–277, 2008.
647 32. Ward K.M. and Balaban R.S. Determination of pH using water protons and chemical ex-
648 change dependent saturation transfer (CEST). *Magn Reson Med*, 44(5): 799–802, 2000.
649 33. Helms G., Dathe H., and Dechent P. Modeling the influence of TR and excitation flip angle
650 on the magnetization transfer ratio (MTR) in human brain obtained from 3D spoiled gradient
651 echo MRI. *Magn Reson Med*, 64(1): 177–185, 2010.
652 34. Chen J.T., Kuhlmann T., Jansen G.H., Collins D.L., Atkins H.L., Freedman M.S., O'Connor
653 P.W., Arnold D.L., and Canadian MS/BMT Study Group. Voxel-based analysis of the evolution
654 of magnetization transfer ratio to quantify remyelination and demyelination with histopatholog-
655 ical validation in a multiple sclerosis lesion. *NeuroImage*, 36(4): 1152–1158, 2007.
656 35. Schmierer K., Tozer D.J., Scaravilli F., Altmann D.R., Barker G.J., Tofts P.S., and Miller D.H.
657 Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. *J Magn
658 Reson Imag*, 26(1): 41–51, 2007.
659 36. Vavasour I.M., Laule C., Li D.K.B., Traboulsee A.L., and MacKay A.L. Is the magnetization
660 transfer ratio a marker for myelin in multiple sclerosis? *J Magn Reson Imaging*, 33(3):710–
661 718, 2011.
662 37. Gareau P.J., Rutt B.K., Karlik S.J., and Mitchell J.R. Magnetization transfer and multicom-
663 ponent T2 relaxation measurements with histopathologic correlation in an experimental model
664 of MS. *J Magn Reson Imaging*, 11(6): 586–595, 2000.
665 38. Vavasour I.M., Chang K.L., Combes A.J.E., and et al. Water content changes in new multiple
666 sclerosis lesions have a minimal effect on the determination of myelin water fraction values.
667 *J Neuroimaging*, 31(6):1119–1125, 2021.
668 39. Dal-Bianco A., Grabner G., Kronnenwetter C., Weber M., Höftberger R., Berger T., Auff E.,
669 Leutmezer F., Trattnig S., Lassmann H., and Bagnato F. Slow expansion of multiple sclerosis
670 iron rim lesions: Pathology and 7T magnetic resonance imaging. *Acta Neuropathol*, 133(1):
671 25–42, 2017.
672 40. Kornek B., Storch M.K., Weissert R., Wallstroem E., Steffler A., Olsson T., Linington
673 C., Schmidbauer M., and Lassmann H. Multiple sclerosis and chronic autoimmune en-
674 cephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and
675 remyelinated lesions. *Am J Pathol*, 157(1): 267–276, 2000.
676 41. Yao T., Nguyen T.D., Pandya S., Zhang Y., Rúa S.H., Kovanilkaya I., Kuceyeski A., Liu Z.,
677 and Wang Y. Combining quantitative susceptibility mapping with automatic zero reference
678 (QSMO) and myelin water fraction imaging to quantify iron-related myelin damage in chronic
679 active MS lesions. *AJNR Am J Neuroradiol*, 39(2): 303–310, 2018.
680 42. Absinta M., Sati P., and Reich D.S. Persistent 7-tesla phase rim predicts poor outcome in
681 new multiple sclerosis patient lesions. *J Clin Invest*, 126(7): 2597–2609, 2016.
682 43. Chang A., Staugaitis S.M., Dutta R., Batt C.E., Easley K.E., Chomyk A.M., Yong V.W., Fox
683 R.J., Kidd G.J., and Trapp B.D. Cortical remyelination: A new target for repair therapies in
684 multiple sclerosis. *Ann Neurol*, 72(6): 918–926, 2012.
685 44. Bagnato F., Hametner S., Boyd E., Endmayr V., Shi Y., Ikonomidou V., Chen G., Pawate S.,
686 Lassmann H., Smith S., and Welch E.B. Unentangling the R2* contrast in multiple sclerosis:
687 a combined MRI-histology study at 7.0 Tesla. *PLoS One*, 13(3): e0193839, 2018.
688 45. Lee J., Nam Y., Choi J.Y., Kim E.Y., Oh S.H., and Kim D.H. Mechanisms of T2* anisotropy
689 and gradient echo myelin water imaging. *NMR Biomed*, 30: e3513, 2017.
690 46. Ouellette R., Mangeat G., Polyak I., and et al. Validation of rapid magnetic resonance myelin
691 imaging in multiple sclerosis. *Ann Neurol*, 87(5):710–724, 2020.

- 692 47. West D.J., Teixeira R.P.A.G., Wood T.C., Hajnal J.V., Tournier J.D., and Malik S.J. Inherent
693 and unpredictable bias in multi-component DESPOT myelin water fraction estimation. *Neu-*
694 *rolmage*, 195: 78–88, 2019.
- 695 48. Nam Y., Kim D.H., and Lee J. Physiological noise compensation in gradient-echo myelin
696 water imaging. *NeuroImage*, 120: 345–349, 2015.
- 697 49. Alonso-Ortiz E., Levesque I.R., Paquin R., and Pike G.B. Field inhomogeneity correction for
698 gradient echo myelin water fraction imaging. *Magn Reson Med*, 78(1): 49–57, 2017.
- 699 50. Dvorak A.V., Wiggermann V., Gilbert G., and et al. Multispin echo T2 relaxation imaging with
700 compressed sensing (METRICS) for rapid myelin water imaging. *Magn Reson Med*, 84(3):
701 1264–1279, 2020.